MarketPeel
Insider Trading Intelligence
NF

Nathan B. Fountain

ABOS
DIRECTOR · ACUMEN PHARMACEUTICALS, INC. · CIK 0001869596
FILING MIX · LIFETIME90%/10%
BUYS
9
SELLS
1
TOTAL VALUE
$114.3K
COMPANIES
1
ACTIVE SINCE
Jun 2021
HOLDINGS NOW
48,150
AVG SELL PX
$2.23
TRADE KIND
SHOWING 10 / 10
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons
Forward-return performance of every backtestable P/S trade by Nathan B. Fountain, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+0.00%-6.24%+0.62%-6.85%-6.85%
14d1+0.00%-8.37%-0.43%-7.93%-7.93%
30d1+0.00%-25.79%+2.04%-27.83%-27.83%
60d1+0.00%-22.82%+4.65%-27.48%-27.48%
90d1+0.00%-25.00%-0.67%-24.33%-24.33%
180d1+0.00%-66.68%+11.09%-77.77%-77.77%
1y1+0.00%-72.77%-10.21%-62.56%-62.56%
2y1+0.00%-75.00%+4.69%-79.69%-79.69%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ABOS · 48,150 shares · as of Jun 9, 2026
013,63827,27540,91354,55020222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 9 buys / 1 sellsCOVERAGE · 21 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ABOS
ACUMEN PHARMACEUTICALS, INC.
SALE
6,400$2.23$14.3K48,150Jun 9, 2026Jun 10, 2026View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
53,25053,250Jun 3, 2026Jun 5, 2026View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
35,50054,550Jun 3, 2026Jun 5, 2026View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
19,50019,500Jun 4, 2025Jun 5, 2025View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
12,80019,050Jun 4, 2025Jun 5, 2025View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
25,00025,000Jun 10, 2024Jun 10, 2024View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
25,00025,000Jun 6, 2023Jun 7, 2023View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
25,00025,000Jun 15, 2022Jun 17, 2022View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
PURCHASE
6,250$16.00$100.0K6,250Jul 6, 2021Jul 8, 2021View →
ABOS
ACUMEN PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
34,00034,000Jun 30, 2021Jul 2, 2021View →
Other insiders · ABOS
Loading peer insiders…
About this filer
CIK 0001869596
ROLE
Director
PRIMARY
ABOS
COMPANIES
1
ACTIVE SINCE
Jun 2021
MARKETPEEL · /INSIDER/0001869596DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback